Mira Pharmaceuticals, INC 8-K filings

Mira Pharmaceuticals announced positive toxicokinetic findings from a 7-day dog study for its obesity drug candidate SKNY-1, de-risking dose selection for future development.

Mira Pharmaceuticals received a notice from Nasdaq indicating it no longer meets the minimum $1 bid price requirement, with 180 days to regain compliance.

Mira Pharmaceuticals announced positive preclinical study results for its oral drug candidate, MIRA-55, showing favorable bioavailability and distribution for chronic inflammatory pain treatment.

Mira Pharmaceuticals announced positive preclinical study results for its oral drug candidate SKNY-1, showing favorable bioavailability, brain penetration, and potential for once-daily dosing for obesity and addiction.

MIRA Pharmaceuticals announced new preclinical data showing Mira-55 has a distinct mechanism of action and anxiolytic activity compared to THC.

MIRA Pharmaceuticals announced the submission of its Phase 2a clinical trial protocol for Ketamir-2 to the FDA for treating chemotherapy-induced peripheral neuropathy (CIPN).

MIRA Pharmaceuticals has appointed Andriy Mushak as its new fractional Chief Financial Officer, effective June 6, 2026.

Mira Pharmaceuticals has executed an Amended and Restated Exclusive License Agreement, securing worldwide exclusive rights to its MIRA-55 and SKNY-1 development programs.

Mira Pharmaceuticals has secured worldwide rights for its Ketamir-2 drug candidate, expanding its intellectual property portfolio across major global markets ahead of Phase 2a development.

Mira Pharmaceuticals announced positive unblinded results from its completed Phase 1 clinical trial for Ketamir-2, a selective oral NMDA receptor modulator.

Mira Pharmaceuticals reports positive preclinical findings for its investigational drug SKNY-1, showing significant weight loss and behavioral improvements in zebrafish models.

MIRA Pharmaceuticals reports new preclinical data for Mira-55 showing no THCor Rimonabant-associated central nervous system side effects, supporting its planned IND submission for inflammatory pain.

MIRA Pharmaceuticals announced the successful completion of Phase 1 dosing for Ketamir-2, showing favorable safety and tolerability.

MIRA Pharmaceuticals announced the initiation of final dosing for its Phase 1 Ketamir-2 trial and outlined plans for Phase 2a, partnering, and preclinical pipeline advancement.

MIRA Pharmaceuticals' Board approved significant incentive awards for CEO Erez Aminov, recognizing 2025 achievements including clinical progress, capital raising, and a strategic acquisition.

MIRA Pharmaceuticals, Inc. announced an increase of $15.2 million to its At The Market equity offering program, expanding its capital raising capacity.

MIRA Pharmaceuticals has initiated the multiple ascending dose portion of its Phase 1 study for oral Ketamir-2 and selected chemotherapy-induced neuropathic pain as its lead Phase 2a indication.

MIRA Pharmaceuticals, Inc. successfully raised approximately $3.8 million through the sale of 1.75 million common shares at a 66% premium to institutional investors.

MIRA Pharmaceuticals announced preclinical data showing its oral Mira-55 drug normalized pain and significantly reduced inflammation, surpassing injected morphine in an animal model.

MIRA Pharmaceuticals completed its acquisition of SKNY Pharmaceuticals, adding three new drug candidates and strengthening its balance sheet with a $5 million contribution, while also addressing Nasdaq listing compliance.

MIRA Pharmaceuticals announced positive topline results from its Phase 1 single ascending dose study of oral Ketamir-2, demonstrating safety, tolerability, and favorable pharmacokinetics.

MIRA Pharmaceuticals announced positive proof-of-concept study results for its oral drug candidate, Ketamir-2, demonstrating restored normalized behavior in stressed animals in a PTSD model.

MIRA Pharmaceuticals' shareholders approved the acquisition of SKNY Pharmaceuticals and amendments to its 2022 Omnibus Incentive Plan at its Annual Meeting.

MIRA Pharmaceuticals announced the successful completion of the Single Ascending Dose portion of its Phase 1 clinical trial for oral Ketamir-2, showing no safety concerns and progressing to the Multiple Ascending Dose stage.

MIRA Pharmaceuticals announced its lead drug candidate, Ketamir-2, demonstrated superior efficacy in preclinical neuropathic pain models compared to existing treatments, with a manuscript accepted for peer-reviewed publication.

MIRA Pharmaceuticals announced preclinical data showing its new topical Ketamir-2 formulation significantly reduced pain in animals, demonstrating comparable efficacy to injected morphine.

MIRA Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Ketamir-2, enabling U.S.-based clinical trials for neuropathic pain.

MIRA Pharmaceuticals, Inc. announced new preclinical results for its oral drug candidate SKNY-1, showing a clear reversal of anxiety-related behavior in an animal model, distinguishing it from previous CB1-targeting drugs with CNS side effects.

MIRA Pharmaceuticals, Inc. has successfully raised approximately $2.0 million by selling over 1.5 million shares of common stock to an institutional investor at a premium to the prior day's close.

MIRA Pharmaceuticals announced positive preclinical results for its non-psychoactive pain relief drug candidate Mira-55, demonstrating efficacy comparable to morphine without opioid risks, alongside significant progress on its acquisition of SKNY Pharmaceuticals.